Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2066352 | Toxicon | 2010 | 10 Pages |
Abstract
The aim of this study was to evaluate the anti-tumor activity of Amblyomin-X, a serine protease Kunitz-type inhibitor. Amblyomin-X induced tumor mass regression and decreased number of metastatic events in a B16F10 murine melanoma model. Alterations on expression of several genes related to cell cycle were observed when two tumor cell lines were treated with Amblyomin-X. PSMB2, which encodes a proteasome subunit, was differentially expressed, in agreement to inhibition of proteasomal activity in both cell lines. In conclusion, our results indicate that Amblyomin-X selectively acts on tumor cells by inducing apoptotic cell death, possibly by targeting the ubiquitin-proteasome system.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Ana Marisa Chudzinski-Tavassi, Paulo Luis De-Sá-Júnior, Simone Michaela Simons, Durvanei Augusto Maria, Janaina de Souza Ventura, Isabel de Fátima Correia Batista, Fernanda Faria, Esther Durães, Eduardo Moraes Reis, Marilene Demasi,